TNFRSF4 and neoplasm: Marabelle et al. also reported that intratumoral co-injection of anti-CTLA-4 and anti-OX40 Ab together with CpG depleted tumor-infiltrating Tregs and concluded that immunomodulating Ab could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response20.